A detailed history of Wells Fargo & Company transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Wells Fargo & Company holds 14,376 shares of GALT stock, worth $14,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,376
Previous 14,368 0.06%
Holding current value
$14,951
Previous $32,000 21.88%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.04 - $2.86 $16 - $22
8 Added 0.06%
14,376 $39,000
Q2 2024

Aug 13, 2024

BUY
$2.13 - $4.2 $15,152 - $29,878
7,114 Added 98.07%
14,368 $32,000
Q1 2024

May 10, 2024

SELL
$1.6 - $2.44 $524 - $800
-328 Reduced 4.33%
7,254 $17,000
Q4 2023

Feb 09, 2024

SELL
$1.6 - $2.18 $728 - $991
-455 Reduced 5.66%
7,582 $12,000
Q3 2023

Nov 13, 2023

BUY
$1.38 - $1.97 $3,571 - $5,098
2,588 Added 47.49%
8,037 $15,000
Q2 2023

Aug 15, 2023

SELL
$1.32 - $2.08 $27,362 - $43,116
-20,729 Reduced 79.18%
5,449 $7,000
Q1 2023

May 12, 2023

BUY
$1.1 - $2.4 $21,745 - $47,445
19,769 Added 308.46%
26,178 $54,000
Q4 2022

Feb 13, 2023

SELL
$1.03 - $1.66 $2,176 - $3,507
-2,113 Reduced 24.79%
6,409 $7,000
Q3 2022

Nov 14, 2022

SELL
$1.31 - $2.48 $7 - $14
-6 Reduced 0.07%
8,522 $13,000
Q2 2022

Aug 12, 2022

BUY
$1.19 - $1.74 $28 - $41
24 Added 0.28%
8,528 $11,000
Q1 2022

May 16, 2022

BUY
$1.61 - $2.31 $1 - $2
1 Added 0.01%
8,504 $13,000
Q4 2021

Feb 14, 2022

BUY
$2.07 - $3.8 $12 - $22
6 Added 0.07%
8,503 $18,000
Q3 2021

Nov 15, 2021

SELL
$2.59 - $4.15 $9,176 - $14,703
-3,543 Reduced 29.43%
8,497 $33,000
Q2 2021

Aug 16, 2021

SELL
$2.07 - $5.1 $17,156 - $42,268
-8,288 Reduced 40.77%
12,040 $39,000
Q1 2021

May 13, 2021

SELL
$1.96 - $2.57 $149,914 - $196,571
-76,487 Reduced 79.0%
20,328 $45,000
Q4 2020

Feb 09, 2021

BUY
$2.24 - $2.87 $88,639 - $113,568
39,571 Added 69.13%
96,815 $217,000
Q3 2020

Nov 05, 2020

SELL
$2.53 - $3.64 $27,076 - $38,955
-10,702 Reduced 15.75%
57,244 $153,000
Q2 2020

Aug 13, 2020

BUY
$1.66 - $3.15 $36,998 - $70,207
22,288 Added 48.82%
67,946 $209,000
Q1 2020

May 14, 2020

BUY
$1.51 - $3.0 $68,943 - $136,974
45,658 New
45,658 $89,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $61.8M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.